API | emicerfont

emicerfont Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Emicerfont (GW-876,008) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors: CRF1 and CRF2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. ^Wikipedia

Chemistry

SMILES: COc1ccc(N2CCc3c2nc(C)cc3n4ccc(n4)N5CCNC5=O)c(C)c1
InChIKey: JFHJGXQFESYQGY-UHFFFAOYSA-N
Mol. Mass: 404.47
ALogP: 3.12 Partition coefficient
ChEMBL Molecule:
emicerfont

More Chemistry

Pharmacology

Mechanism of Action:
- Corticotropin-releasing factor receptor 1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

emicerfont | gw876008 | gw 876008 | gw-876008 | gw876008x

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Healthy Volunteers (Phase 1)

Irritable Bowel Syndrome (Phase 2)

Phobia, Social (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 10
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue